Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $56.5 million.

  • Day One Biopharmaceuticals' Total Current Liabilities rose 4207.07% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 4207.07%. This contributed to the annual value of $73.5 million for FY2024, which is 14891.89% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Total Current Liabilities is $56.5 million, which was up 4207.07% from $51.2 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Total Current Liabilities' 5-year high stood at $93.7 million during Q2 2024, with a 5-year trough of $8.2 million in Q1 2022.
  • In the last 4 years, Day One Biopharmaceuticals' Total Current Liabilities had a median value of $29.5 million in 2023 and averaged $36.6 million.
  • In the last 5 years, Day One Biopharmaceuticals' Total Current Liabilities soared by 28228.62% in 2024 and then tumbled by 4533.86% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Total Current Liabilities (Quarter) stood at $16.6 million in 2022, then soared by 77.6% to $29.5 million in 2023, then surged by 148.92% to $73.5 million in 2024, then decreased by 23.12% to $56.5 million in 2025.
  • Its Total Current Liabilities stands at $56.5 million for Q3 2025, versus $51.2 million for Q2 2025 and $47.9 million for Q1 2025.